Delivery Order SPE2DB20D2104-SPE2DB25FNBNK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,059.09 to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 60 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 60 mg tablets (30-count units) with a ceiling value of $1,142.40. The contract utilizes firm fixed price terms and carries an ultimate completion date of July 1, 2025. This non-set-aside, competitively awarded delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the...
- The Defense Logistics Agency awarded a delivery order valued at $2,705.32 to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 30 mg tablets (UU 21S) on August 19, 2025, with an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Pyridostigmine Bromide 60 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $1,119.93 and an ultimate completion date of September 24, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $4,246.44 to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 60 mg tablets in a 30-count configuration. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location....
- The Defense Logistics Agency awarded a $11,998.92 delivery order to AmerisourceBergen Drug Corp for Pyridostigmine Bromide 60 mg tablets (30-count packaging) on August 7, 2025, with completion expected by August 8, 2025. This competitive award, issued without set-aside designation, reflects a firm fixed price contract type and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 30 mg tablets, with a ceiling value of $1,810.85. The award, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $14,166.32 to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 30 mg tablets with an ultimate completion date of September 19, 2025. This is a firm fixed-price delivery order under a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pyridostigmine Bromide 60 mg tablets (30-count packages) on September 5, 2025, with a ceiling value of $2,051.45 and ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,105.04 for Pyridostigmine Extended Release 180 mg tablets in quantities of 30 units on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order represents a non-competitive award issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBNKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Pyridostigmine Bromide 60 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a ceiling value of $1,090.09 and has an ultimate completion date of September 26, 2025. The contract utilizes firm fixed price terms and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and is registered in the System for Award Management. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply portfolio supporting military and federal healthcare systems. Pyridostigmine bromide is a cholinesterase inhibitor medication used primarily in the treatment of myasthenia gravis and other neuromuscular conditions. The award reflects the company's established capacity to fulfill federal medical supply requirements through its prime vendor relationship with DLA, enabling rapid delivery of pharmaceutical products to support Defense Health Agency operations and other government healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/25/25 |